Stocks · News reference
MediciNova Completes Last Patient, Last Visit In The Double-Blind Portion Of COMBAT-ALS Phase 2B/3 Clinical Trial Evaluating MN-166 For The Treatment Of Amyotrophic Lateral Sclerosis
A total of 234 participants were randomized to two treatment arms at clinical sites in the United States and Canada. Participants who remain active in the study are continuing treatment with MN-166 in the Open-Label
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN rated Market Perform at $25.
Roth Capital Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $6
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on MediciNova (NASDAQ:MNOV) with a Buy rating and announces Price Target of $6.